Management of Peritoneal Metastases of Colorectal Cancer, Literature Review

Abstract

**Background:** Management of peritoneal metastases from colorectal cancer is a highly debatable subject. Treatment options of this disease range from systemic chemotherapy, surgery followed by chemotherapy to resection, then chemotherapy and intraperitoneal chemotherapy with hyperthermia.

**Aim of the study:** To review guidelines and updated studies on management of peritoneal carcinomatosis caused by colorectal cancer.

**Methodology:** The study includes review of systematic reviews, multi-institutional data collection, randomized controlled trials and clinical reviews.

**Results:** A total number of 893 patients with advanced colon cancer who presented as stage IV with peritoneal metastases as first presentation have been involved in this study. The most significant finding in these studies is the role of systemic chemotherapy either given as neoadjuvant, adjuvant or combined modality. The addition of Bevacizumab as vascular endothelial growth factor (VEGF) was a significant factor in improving response rate and survival. The use of Mitomycin C (MMC) as a component of HIPEC: hyperthermic intraperitoneal chemotherapy was better than Oxaliplatin in terms of median overall survival.

**Conclusion:** The best treatment strategy for these patients is to give neoadjuvant chemotherapy (no specific regime showed superiority over others) with VEGF Bevacizumab aiming at maximum cytoreduction, and then doing HIPEC using Mitomycin C as a chemotherapeutic agent followed by adjuvant chemotherapy including Bevacizumab as VEGF component.

**Keywords:** Colorectal cancer; Peritoneal metastases; Chemotherapy; Surgery; Hyperthermia

Introduction

10% -15% of patients initially diagnosed with colorectal cancer have peritoneal deposits at time of initial diagnosis [1]. Peritoneum represents the next place of metastatic disease in colorectal cancer after liver [2]. For long time, peritoneal metastases of colon cancer is considered a terminal stage disease with palliative care as the only modality for this disease [3]. In addition to the poor overall survival of patients with colon cancer who present with peritoneal metastases, there are no definite treatment strategies for this group of patients [4].

**Purpose of the Study and Rationale**

The main purpose of this study is to find the best treatment strategy of colon cancer with peritoneal carcinomatosis. I reviewed the current state of art policies and treatment guidelines for colorectal peritoneal carcinomatosis, aiming to reach a reasonable treatment approach helping these patients to achieve better response and survival.

**Methodology**

An internet web search for all high quality and evidence based sites like Pubmed, Medline, and Ovid. Search words included: Cancer Colon peritoneal carcinomatosis, surgery, chemotherapy, hyperthermia, 2014, prospective. High rank research publications including but not limited to: systematic reviews, meta-analysis, prospective randomized studies, cohort studies, and case reports. A proper organization of articles based on its relevance to the subject, date of publications, power of the study, and rank of journal.

**Results**

Cochrane review, 5 articles, non-related, Pubmed search 1164 articles search words : colorectal peritoneal carcinomatosis, chemotherapy, surgery hyperthermia 2014. 14 articles with colorectal peritoneal carcinomatosis chemotherapy surgery hyperthermia 2014 prospective.
The most significant finding in these studies is the role of systemic chemotherapy either given as neoadjuvant, adjuvant or combined modality, as seen by Passot G et al. [7] and Kuipers A et al. [8], in both studies, patients who received neoadjuvant systemic chemotherapy achieved the highest 5 years overall survival rates (75%) [7] which is incredibly high as compared to known figures of 11% [9].

Furthermore, the choice of systemic chemotherapy regimen was a significant factor in disease response/survival as shown by Ceelen W et al. [6] whereby the median overall survival (MOS) was significantly higher in neoadjuvant chemotherapy and Bevacisumab versus those under chemotherapy alone (P = 0.021). Disease burden was also a strong independent prognostic variable with the highest response and survival rates among those who presented with minimal or low disease burden. So Passot G et al. [7] found that PCR (Pathological complete response) induced by neoadjuvant chemotherapy is an independent prognostic factor for 5 years overall survival rates (75%). No other factors affect MOS. The only contribution of HIPEC in response rate/survival was in the type of chemotherapy chosen for HIPEC, so Villaverde et al. [5] found that, MOS: 54.3 months in MMC (mitomycin group), and 28.2 months in Oxaliplatin group (both groups have low volume peritoneal disease) (Table 1).

Table 1: Summarizes the findings in reviewed articles related to the subject of research.

<table>
<thead>
<tr>
<th>Study Author</th>
<th>Methodology</th>
<th>Number of Patients</th>
<th>Treatment Arm(s)</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Villaverde et al.</td>
<td>Retrospective</td>
<td>539</td>
<td>a. HIPEC (a) with MMC (b)</td>
<td>MOS: 54.3 months in MMC group, and 28.2 months in Oxaliplatin group (both groups have low volume peritoneal disease).</td>
</tr>
<tr>
<td>Ceelen W et al.</td>
<td>Prospective Non-Randomised</td>
<td>166</td>
<td>a. HIPEC with neoadjuvant chemotherapy alone.</td>
<td>MOS was significantly higher in neoadjuvant chemotherapy and Bevacisumab versus those under chemotherapy alone (P = 0.021).</td>
</tr>
<tr>
<td>Passot G et al.</td>
<td>Prospective Non-Randomised</td>
<td>115</td>
<td>a. Neoadjuvant Irinotecan then surgery +/- HIPEC</td>
<td>Pcr (d) induced by neoadjuvant chemotherapy is an independent prognostic factor for 5 years over all survival rates (75%). No other factors affect MOS</td>
</tr>
<tr>
<td>Kuipers A et al.</td>
<td>Review article</td>
<td>73</td>
<td>a. Neoadjuvant chemotherapy + CRS (e) + HIPEC + adjuvant chemotherapy.</td>
<td>The least PFS (f) and MOS were found in group 4 (who did not get any systemic chemotherapy. (PFS: 15 versus 4 months, P = 0.024; OS: median 30 versus 14 months, P = 0.015)</td>
</tr>
</tbody>
</table>

HIPEC: Cytoreductive Surgery and Hyper Thermic Intra Peritoneal Chemotherapy; MMC: Mitomycin C Chemotherapy; MOC: Median Overall Survival; PCR: Pathological Complete Response; CRS: Cytoreductive Surgery; PFS: Progression Free Survival

Discussion

Patients diagnosed with colon cancer are staged as stage IV (M1B) if they have peritoneal metastases. A poor survival rate (11%) 5 years overall survival has been found for this stage of colon cancer [9]. Even a more conservative figures of poor survival rates for this stage of colon cancer have been published (5 years survival rates of 0% and median survival rate of 6-8 months) [10,11]. One of the major prognostic factors of survival in patients with colon cancer and peritoneal metastases is extent of disease, which is shown clearly in many research articles [12]. So it’s prudent to treat those patients with maximal cytoreduction in addition to other treatment options like neoadjuvant, and adjuvant chemotherapy and HIPEC [13].

From review of current literature it seemed that the best treatment options for these patients is to attempts systemic treatment (either preoperative, postoperative chemotherapy, or both) as seen by Passot G [7], and Kuipers A et al. [8], in both studies, patients who received neoadjuvant systemic chemotherapy achieved the highest 5 years overall survival rates (75%) Passot G et al. [7], which is incredibly high as compared to known figures of 11% [9]. On the other hand, Kuipers A et al. [8] found that; the least MOS and PFS was found in a group of patients who did not get any systemic chemotherapy as compared to those who received systemic chemotherapy (PFS: 15 versus 4 months, P = 0.024; OS: median 30 versus 14 months, P = 0.015) for those who received systemic chemotherapy (either neoadjuvant, adjuvant chemotherapy or both respectively.

The choice of systemic chemotherapy either in neoadjuvant, adjuvant setting or both can affect disease response and survival, so Ceelen W et al. [6] found that the addition of vascular endothelial growth factor (VEGF) Bevacisumab adds an advantage to the MOS, which was shown as a significantly higher MOS in neoadjuvant chemotherapy and Bevacisumab versus those under chemotherapy alone (P: =0.021). Not only the choice of systemic chemotherapy had an influence on response and survival of these patients, but also the choice of chemotherapeutic agent for HIPEC, as shown by Villaverde et al. [5], who found that, the MOS was 54.3 months in MMC group, and 28.2 months in Oxaliplatin group (both groups have low volume peritoneal disease).

Conclusion

The best treatment option for patients with cancer colon and...
peritoneal metastases has to be more researched to achieve the best response rate and survival. From current review of literature (as of 2014 research data), the best treatment strategy for these patients is to give neoadjuvant chemotherapy (no specific regime showed superiority over others) with VEGF Bevazucimab aiming at maximum cytoreduction, then doing HIPEC using Mitomycin C as chemotherapeutic agent followed by adjuvant chemotherapy including Bevazicumb as VEGF component.

**Recommendation**

It’s recommended to do more prospective studies on these patients with advanced colon cancer and peritoneal metastases adding different chemotherapeutic agents (like Capecitabine), targeted agents (like Ceutximab) and may be changing the technique or chemotherapeutic agents in HIPEC.

**References**